Search

Your search keyword '"Munshi, Nikhil C."' showing total 3,517 results
Start Over Author "Munshi, Nikhil C."
3,517 results on '"Munshi, Nikhil C."'

3. Author Correction: The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells

Author

Zhu, Di, Wang, Zhongqiu, Zhao, Jian-Jun, Calimeri, Teresa, Meng, Jiang, Hideshima, Teru, Fulciniti, Mariateresa, Kang, Yue, Ficarro, Scott B., Tai, Yu-Tzu, Hunter, Zachary, McMilin, Douglas, Tong, Haoxuan, Mitsiades, Constantine S., Wu, Catherine J., Treon, Steven P., Dorfman, David M., Pinkus, Geraldine, Munshi, Nikhil C., Tassone, Pierfrancesco, Marto, Jarrod A., Anderson, Kenneth C., and Carrasco, Ruben D.

Published
2024
Full Text
View/download PDF

5. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Author

Deng, Shuhui, Derebail, Sanika, Weiler, Vera Joy, Fong Ng, Jessica, Maroto-Martin, Elena, Chatterjee, Madhumouli, Giorgetti, Giulia, Chakraborty, Chandraditya, Kalhotra, Poonam, Du, Ting, Yao, Yao, Prabhala, Rao, Shammas, Masood, Gulla, Annamaria, Aktas Samur, Anil, Samur, Mehmet Kemal, Qiu, Lugui, Anderson, Kenneth C., Fulciniti, Mariateresa, and Munshi, Nikhil C.

Published
2024
Full Text
View/download PDF

6. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Author

Lin, Yi, Raje, Noopur S., Berdeja, Jesús G., Siegel, David S., Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Massaro, Monica, Petrocca, Fabio, Yeri, Ashish, Finney, Olivia, Caia, Andrea, Yang, Zhihong, Martin, Nathan, Campbell, Timothy B., Rytlewski, Julie, Fuller, Jaymes, Hege, Kristen, Munshi, Nikhil C., and Kochenderfer, James N.

Published
2023
Full Text
View/download PDF

7. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Author

Gulla, Annamaria, Morelli, Eugenio, Johnstone, Megan, Turi, Marcello, Samur, Mehmet K., Botta, Cirino, Cifric, Selma, Folino, Pietro, Vinaixa, Delaney, Barello, Francesca, Clericuzio, Cole, Favasuli, Vanessa Katia, Maisano, Domenico, Talluri, Srikanth, Prabhala, Rao, Bianchi, Giada, Fulciniti, Mariateresa, Wen, Kenneth, Kurata, Keiji, Liu, Jiye, Penailillo, Johany, Bragoni, Alberto, Sapino, Anna, Richardson, Paul G., Chauhan, Dharminder, Carrasco, Ruben D., Hideshima, Teru, Munshi, Nikhil C., and Anderson, Kenneth C.

Published
2024
Full Text
View/download PDF

8. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Author

Delforge, Michel, Shah, Nina, San F. Miguel, Jesús, Braverman, Julia, Dhanda, Devender S, Shi, Ling, Guo, Shien, Yu, Peiwen, Liao, Weiqin, Campbell, Timothy B, and Munshi, Nikhil C

Subjects
Chronic Pain, Hematology, Pain Research, Behavioral and Social Science, Rare Diseases, Clinical Trials and Supportive Activities, Health Services, Cancer, Clinical Research, Fatigue, Humans, Multiple Myeloma, Pain, Quality of Life, Receptors, Chimeric Antigen
Abstract

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the EuroQol 5-dimension 5-level instrument, were administered at screening, baseline (≤72 hours before or same day as lymphodepletion), day of ide-cel treatment, and after ide-cel treatment. Mean changes from baseline that exceeded the predetermined threshold of minimally important difference were deemed clinically meaningful. The proportions of patients experiencing clinically meaningful changes in HRQoL were assessed using within-patient change thresholds. Time to stable improvement (≥2 consecutive visits with clinically meaningful HRQoL improvements) was analyzed by using the Kaplan-Meier method. A total of 126 (98%) of 128 patients treated with ide-cel were included in the HRQoL analysis. Pretreatment baseline RRMM burden was high and meaningfully worse than that in the age- and sex-weighted general population. Statistically significant and clinically meaningful improvements from baseline were observed by month 1 for pain (-8.9) and disease symptoms (-10.2), and by month 2 for fatigue (-7.2), physical functioning (6.1), cognitive functioning (6.7), and global health status/QoL (8.0). Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For triple-class exposed patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL. This study was registered at Clinicaltrials.gov as #NCT03361748.

Published
2022

13. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma

Author

Kumar, Subodh, Zhao, Jiangning, Talluri, Srikanth, Buon, Leutz, Mu, Shidai, Potluri, Lakshmi B., Liao, Chengcheng, Shi, Jialan, Chakraborty, Chandraditya, Gonzalez, Gabriel B., Tai, Yu-Tzu, Patel, Jaymin, Pal, Jagannath, Mashimo, Hiroshi, Samur, Mehmet K., Munshi, Nikhil C., and Shammas, Masood A.

Published
2023
Full Text
View/download PDF

15. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Author

Yao, Yao, Ng, Jessica Fong, Park, Woojun Daniel, Samur, Mehmet, Morelli, Eugenio, Encinas Mayoral, Jessica, Chyra, Zuzana, Xu, Yan, Derebail, Sanika, Epstein, Charles, Nabet, Behnam, Chesi, Marta, Gray, Nathanael S., Young, Richard A., Kwiatkowski, Nicholas, Mitsiades, Constantine, Anderson, Kenneth C., Lin, Charles Y., Munshi, Nikhil C., and Fulciniti, Mariateresa

Published
2023
Full Text
View/download PDF

17. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

18. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Author

Samur, Mehmet Kemal, Roncador, Marco, Aktas Samur, Anil, Fulciniti, Mariateresa, Bazarbachi, Abdul Hamid, Szalat, Raphael, Shammas, Masood A., Sperling, Adam S., Richardson, Paul G., Magrangeas, Florence, Minvielle, Stephane, Perrot, Aurore, Corre, Jill, Moreau, Philippe, Thakurta, Anjan, Parmigiani, Giovanni, Anderson, Kenneth C., Avet-Loiseau, Hervé, and Munshi, Nikhil C.

Published
2023
Full Text
View/download PDF

20. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Author

Morelli, Eugenio, Fulciniti, Mariateresa, Samur, Mehmet K., Ribeiro, Caroline F., Wert-Lamas, Leon, Henninger, Jon E., Gullà, Annamaria, Aktas-Samur, Anil, Todoerti, Katia, Talluri, Srikanth, Park, Woojun D., Federico, Cinzia, Scionti, Francesca, Amodio, Nicola, Bianchi, Giada, Johnstone, Megan, Liu, Na, Gramegna, Doriana, Maisano, Domenico, Russo, Nicola A., Lin, Charles, Tai, Yu-Tzu, Neri, Antonino, Chauhan, Dharminder, Hideshima, Teru, Shammas, Masood A., Tassone, Pierfrancesco, Gryaznov, Sergei, Young, Richard A., Anderson, Kenneth C., Novina, Carl D., Loda, Massimo, and Munshi, Nikhil C.

Published
2023
Full Text
View/download PDF

23. Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.

Author

La, Jennifer, primary, Hshieh, Tammy, additional, Hamparsumian, Anahid, additional, Zwolinski, Robert, additional, Wood, Jameson, additional, Dharne, Mayuri, additional, Gaziano, J. Michael, additional, Brophy, Mary T., additional, Do, Nhan, additional, Munshi, Nikhil C., additional, Driver, Jane A., additional, Abel, Gregory A., additional, Fillmore, Nathanael, additional, and DuMontier, Clark, additional

Published
2024
Full Text
View/download PDF

25. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

27. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

Author

O'Donnell, Elizabeth K., Shapiro, Yael N., Yee, Andrew J., Nadeem, Omar, Laubach, Jacob P., Branagan, Andrew R., Anderson, Kenneth C., Mo, Clifton C., Munshi, Nikhil C., Ghobrial, Irene M., Sperling, Adam S., Agyemang, Emerentia A., Burke, Jill N., Harrington, Cynthia C., Hu, Bonnie Y., Richardson, Paul G., Raje, Noopur S., and El-Jawahri, Areej

Published
2022
Full Text
View/download PDF

29. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

Author

Waldschmidt, Johannes M., Yee, Andrew J., Vijaykumar, Tushara, Pinto, Ricardo A., Frede, Julia, Anand, Praveen, Bianchi, Giada, Guo, Guangwu, Potdar, Sayalee, Seifer, Charles, Nair, Monica S., Kokkalis, Antonis, Kloeber, Jake A., Shapiro, Samantha, Budano, Lillian, Mann, Mason, Friedman, Robb, Lipe, Brea, Campagnaro, Erica, O’Donnell, Elizabeth K., Zhang, Cheng-Zhong, Laubach, Jacob P., Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C., Raje, Noopur S., Knoechel, Birgit, and Lohr, Jens G.

Published
2022
Full Text
View/download PDF

30. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia

Author

Morelli, Eugenio, Hunter, Zachary R., Fulciniti, Mariateresa, Gullà, Annamaria, Perrotta, Ida Daniela, Zuccalà, Valeria, Federico, Cinzia, Juli, Giada, Manzoni, Martina, Ronchetti, Domenica, Romeo, Enrica, Gallo Cantafio, Maria Eugenia, Soncini, Debora, Maltese, Lorenza, Rossi, Marco, Roccaro, Aldo M., Cea, Michele, Tassone, Pierfrancesco, Neri, Antonino, Treon, Steven C., Munshi, Nikhil C., Viglietto, Giuseppe, and Amodio, Nicola

Published
2022
Full Text
View/download PDF

32. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Author

Raje, Noopur S, Anaissie, Elias, Kumar, Shaji K, Lonial, Sagar, Martin, Thomas, Gertz, Morie A, Krishnan, Amrita, Hari, Parameswaran, Ludwig, Heinz, O'Donnell, Elizabeth, Yee, Andrew, Kaufman, Jonathan L, Cohen, Adam D, Garderet, Laurent, Wechalekar, Ashutosh F, Terpos, Evangelos, Khatry, Navin, Niesvizky, Ruben, Yi, Qing, Joshua, Douglas E, Saikia, Tapan, Leung, Nelson, Engelhardt, Monika, Mothy, Mohamad, Branagan, Andrew, Chari, Ajai, Reiman, Anthony J, Lipe, Brea, Richter, Joshua, Rajkumar, S Vincent, Miguel, Jesús San, Anderson, Kenneth C, Stadtmauer, Edward A, Prabhala, Rao H, McCarthy, Phillip L, and Munshi, Nikhil C

Published
2022
Full Text
View/download PDF

33. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH

Author

Yan, Yuting, Qin, Xiaoqi, Liu, Jiahui, Fan, Huishou, Yan, Wenqiang, Liu, Lanting, Du, Chenxing, Yu, Zhen, Xu, Yan, Hao, Mu, Deng, Shuhui, Sui, Weiwei, Lyu, Rui, Liu, Wei, Wang, Qi, Zou, Dehui, Hu, Linping, Wang, Jianxiang, Tai, Yu-Tzu, Anderson, Kenneth C., Zhang, Lei, Cheng, Tao, Zetterberg, Anders, Munshi, Nikhil C., Qiu, Lugui, and An, Gang

Published
2022
Full Text
View/download PDF

35. Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3′-Kinase/AKT Signaling

Author

Tai, Yu-Tzu, primary, Podar, Klaus, additional, Catley, Laurence, additional, Tseng, Yu-Hua, additional, Akiyama, Masaharu, additional, Shringarpure, Reshma, additional, Burger, Renate, additional, Hideshima, Teru, additional, Chauhan, Dharminder, additional, Mitsiades, Nicholas, additional, Richardson, Paul, additional, Munshi, Nikhil C., additional, Kahn, C. Ronald, additional, Mitsiades, Constantine, additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

36. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications

Author

Tai, Yu-Tzu, primary, Catley, Laurence P., additional, Mitsiades, Constantine S., additional, Burger, Renate, additional, Podar, Klaus, additional, Shringpaure, Reshma, additional, Hideshima, Teru, additional, Chauhan, Dharminder, additional, Hamasaki, Makoto, additional, Ishitsuka, Kenji, additional, Richardson, Paul, additional, Treon, Steven P., additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

37. Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein

Author

Akiyama, Masaharu, primary, Hideshima, Teru, additional, Hayashi, Toshiaki, additional, Tai, Yu-Tzu, additional, Mitsiades, Constantine S., additional, Mitsiades, Nicholas, additional, Chauhan, Dharminder, additional, Richardson, Paul, additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

40. Abstract P24: GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myeloma

Author

Turi, Marcello, primary, Morelli, Eugenio, additional, Johnstone, Megan, additional, Samur, Mehmet K, additional, Botta, Cirino, additional, Cifric, Selma, additional, Folino, Pietro, additional, Vinaixa, Delaney, additional, Barello, Francesca, additional, Clericuzio, Cole, additional, Favasuli, Vanessa K, additional, Maisano, Domenico, additional, Talluri, Srikanth, additional, Prabhala, Rao, additional, Bianchi, Giada, additional, Fulciniti, Mariateresa, additional, Wen, Kenneth, additional, Kurata, Keiji, additional, Liu, Jiye, additional, Penailillo, Johany, additional, Bragoni, Alberto, additional, Sapino, Anna, additional, Richardson, Paul G, additional, Chauhan, Dharminder, additional, Carrasco, Ruben D, additional, Hideshima, Teru, additional, Munshi, Nikhil C, additional, Anderson, Kenneth C, additional, and Gulla, Annamaria, additional

Published
2024
Full Text
View/download PDF

41. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

Author

Ghobrial, Irene M., primary, Gormley, Nicole, additional, Kumar, Shaji K., additional, Mateos, Maria-Victoria, additional, Bergsagel, P. Leif, additional, Chesi, Marta, additional, Dhodapkar, Madhav V., additional, Dispenzieri, Angela, additional, Fonseca, Rafael, additional, Getz, Gad, additional, Kastritis, Efstathios, additional, Kristinsson, Sigurdur Y., additional, Martinez-Climent, Jose Angel, additional, Manier, Salomon, additional, Marinac, Catherine R., additional, Maura, Francesco, additional, Morgan, Gareth J., additional, Davies, Faith E., additional, Nadeem, Omar, additional, Nuvolone, Mario, additional, Paiva, Bruno, additional, O’Donnell, Elizabeth, additional, Prosper, Felipe, additional, Shah, Urvi A., additional, Sklavenitis-Pistofidis, Romanos, additional, Sperling, Adam S., additional, Vassiliou, George S., additional, Munshi, Nikhil C., additional, Castle, Philip E., additional, Anderson, Kenneth C., additional, and San Miguel, Jesus F., additional

Published
2024
Full Text
View/download PDF

42. Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)

Author

Patel, Krina K., primary, Rodríguez-Otero, Paula, additional, Nooka, Ajay K., additional, Callander, Natalie S., additional, Solomon, Scott R., additional, Baz, Rachid, additional, Sborov, Douglas W., additional, Gergis, Usama, additional, Badros, Ashraf Z., additional, Giralt, Sergio A., additional, Pearse, Roger, additional, Abonour, Rafat, additional, Siegel, David S., additional, Larson, Sarah M., additional, Munshi, Nikhil C., additional, Truppel-Hartmann, Anna, additional, Bhatnagar, Rashmi, additional, Wu, Fan, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Mckiver, Mihaela Popa, additional, Jagannath, Sundar, additional, and Ailawadhi, Sikander, additional

Published
2024
Full Text
View/download PDF

43. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Author

Lin, Yi, primary, Usmani, Saad Z., additional, Berdeja, Jesús G, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer E., additional, Cohen, Adam D., additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander M., additional, Munshi, Nikhil C., additional, O'Donnell, Elizabeth, additional, de Oca, Rocio Montes, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Madduri, Deepu, additional, Zhao, Hao, additional, del Corral, Christopher, additional, Koneru, Mythili, additional, Jackson, Carolyn C, additional, Geng, Dong, additional, Martin, Thomas, additional, Jagannath, Sundar, additional, and Wang, Feng, additional

Published
2024
Full Text
View/download PDF

44. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Author

Kelly, Kevin R, Ailawadhi, Sikander, Siegel, David S, Heffner, Leonard T, Somlo, George, Jagannath, Sundar, Zimmerman, Todd M, Munshi, Nikhil C, Madan, Sumit, Chanan-Khan, Asher, Lonial, Sagar, Chandwani, Suraj, Minasyan, Ashot, Ruehle, Markus, Barmaki-Rad, Farima, Abdolzade-Bavil, Afsaneh, Rharbaoui, Faiza, Herrmann-Keiner, Eva, Haeder, Thomas, Wartenberg-Demand, Andrea, and Anderson, Kenneth C

Published
2021
Full Text
View/download PDF

47. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Author

Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

48. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

49. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

Author

Rand, Kristin A, Song, Chi, Dean, Eric, Serie, Daniel J, Curtin, Karen, Sheng, Xin, Hu, Donglei, Huff, Carol Ann, Bernal-Mizrachi, Leon, Tomasson, Michael H, Ailawadhi, Sikander, Singhal, Seema, Pawlish, Karen, Peters, Edward S, Bock, Cathryn H, Stram, Alex, Van Den Berg, David J, Edlund, Christopher K, Conti, David V, Zimmerman, Todd, Hwang, Amie E, Huntsman, Scott, Graff, John, Nooka, Ajay, Kong, Yinfei, Pregja, Silvana L, Berndt, Sonja I, Blot, William J, Carpten, John, Casey, Graham, Chu, Lisa, Diver, W Ryan, Stevens, Victoria L, Lieber, Michael R, Goodman, Phyllis J, Hennis, Anselm JM, Hsing, Ann W, Mehta, Jayesh, Kittles, Rick A, Kolb, Suzanne, Klein, Eric A, Leske, Cristina, Murphy, Adam B, Nemesure, Barbara, Neslund-Dudas, Christine, Strom, Sara S, Vij, Ravi, Rybicki, Benjamin A, Stanford, Janet L, Signorello, Lisa B, Witte, John S, Ambrosone, Christine B, Bhatti, Parveen, John, Esther M, Bernstein, Leslie, Zheng, Wei, Olshan, Andrew F, Hu, Jennifer J, Ziegler, Regina G, Nyante, Sarah J, Bandera, Elisa V, Birmann, Brenda M, Ingles, Sue A, Press, Michael F, Atanackovic, Djordje, Glenn, Martha J, Cannon-Albright, Lisa A, Jones, Brandt, Tricot, Guido, Martin, Thomas G, Kumar, Shaji K, Wolf, Jeffrey L, Deming Halverson, Sandra L, Rothman, Nathaniel, Brooks-Wilson, Angela R, Rajkumar, S Vincent, Kolonel, Laurence N, Chanock, Stephen J, Slager, Susan L, Severson, Richard K, Janakiraman, Nalini, Terebelo, Howard R, Brown, Elizabeth E, De Roos, Anneclaire J, Mohrbacher, Ann F, Colditz, Graham A, Giles, Graham G, Spinelli, John J, Chiu, Brian C, Munshi, Nikhil C, Anderson, Kenneth C, Levy, Joan, Zonder, Jeffrey A, Orlowski, Robert Z, Lonial, Sagar, Camp, Nicola J, Vachon, Celine M, Ziv, Elad, Stram, Daniel O, and Hazelett, Dennis J

Subjects
Biomedical and Clinical Sciences, Cancer, Clinical Research, Genetics, Rare Diseases, Hematology, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Black People, Female, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Middle Aged, Multiple Myeloma, Polycomb Repressive Complex 1, Polymorphism, Single Nucleotide, Protein Serine-Threonine Kinases, Repressor Proteins, Transmembrane Activator and CAML Interactor Protein, White People, Medical and Health Sciences, Epidemiology, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundGenome-wide association studies (GWAS) in European populations have identified genetic risk variants associated with multiple myeloma.MethodsWe performed association testing of common variation in eight regions in 1,318 patients with multiple myeloma and 1,480 controls of European ancestry and 1,305 patients with multiple myeloma and 7,078 controls of African ancestry and conducted a meta-analysis to localize the signals, with epigenetic annotation used to predict functionality.ResultsWe found that variants in 7p15.3, 17p11.2, 22q13.1 were statistically significantly (P < 0.05) associated with multiple myeloma risk in persons of African ancestry and persons of European ancestry, and the variant in 3p22.1 was associated in European ancestry only. In a combined African ancestry-European ancestry meta-analysis, variation in five regions (2p23.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) was statistically significantly associated with multiple myeloma risk. In 3p22.1, the correlated variants clustered within the gene body of ULK4 Correlated variants in 7p15.3 clustered around an enhancer at the 3' end of the CDCA7L transcription termination site. A missense variant at 17p11.2 (rs34562254, Pro251Leu, OR, 1.32; P = 2.93 × 10-7) in TNFRSF13B encodes a lymphocyte-specific protein in the TNF receptor family that interacts with the NF-κB pathway. SNPs correlated with the index signal in 22q13.1 cluster around the promoter and enhancer regions of CBX7 CONCLUSIONS: We found that reported multiple myeloma susceptibility regions contain risk variants important across populations, supporting the use of multiple racial/ethnic groups with different underlying genetic architecture to enhance the localization and identification of putatively functional alleles.ImpactA subset of reported risk loci for multiple myeloma has consistent effects across populations and is likely to be functional. Cancer Epidemiol Biomarkers Prev; 25(12); 1609-18. ©2016 AACR.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results